Management
Calvert Research is composed of a group of senior pharmaceutical and biotechnology executives who are experienced in all facets of our innovative business model.
R.C. McLauchlan
Chairman & Chief Executive Officer
Russ McLauchlan founded Calvert Holdings in March 1996 following twenty-six years in the pharmaceutical and biotechnology industry. He has led the company through its acquisition and internal development of key units resulting in an operation capable of providing significant drug testing and development, capital investment, management, and marketing services for emerging biodiscovery and other business organizations.
Prior to founding Calvert, McLauchlan served as president with an early stage pharmaceutical company and a biotechnology company and as an executive with a multinational pharmaceutical/chemical company. He also served as a board member of national and state biotechnology trade associations.
Michael A. Recny, PhD
President
Dr. Recny is a veteran drug developer with more than 25 years experience in the biotechnology industry. During his career, he has contributed to the research, development and/or commercialization of three FDA approved drugs that have collectively achieved billions in worldwide sales, and to four other drug candidates that have entered human clinical trials. Dr. Recny is responsible for building and managing the portfolio of corporate risk-sharing partnerships for Calvert Research and structures all partnership transactions for the company.
Prior to joining Calvert in 2007, Dr. Recny spent 12 years with Trimeris, Inc. as Vice President of Corporate Development where he led Trimeris’ 1997 internal IPO team and made significant contributions to the development and approval of FUZEON®, Trimeris’ first-in-class HIV antiviral. Together with Trimeris’ General Counsel, Dr. Recny structured one of the first 50/50 co-development and profit share partnerships in the industry with Hoffmann-La Roche, Ltd. (1999) to advance FUZEON from Phase II to worldwide approval and commercial launch in 2003. Prior to Trimeris, Dr. Recny was Director of Protein Biochemistry at Procept, Inc. where he helped structure three collaborative R&D agreements with international pharmaceutical companies over a five year period. Earlier in his career, Dr Recny was a Staff Scientist and Laboratory Head at Genetics Institute, Inc. (now a division of Pfizer, Inc.), where his laboratory was the first to publish the correct protein structure and biological activity of natural and recombinant human erythropoietin.
Dr. Recny attended the University of Rochester as a Joseph C. Wilson Scholar and earned a bachelor’s degree in Biochemistry. He received his Ph.D. in Biochemistry from the University of Illinois, Urbana-Champaign. He conducted postdoctoral work through joint academic appointments at the Dana Farber Cancer Institute (Boston, MA) and Harvard Medical School and is a co-author of numerous per-reviewed publications in the scientific literature. He has also served as a Board Member and business advisor to numerous early stage technology companies.
Andy Burch, President of Calvert Corporate Funding, has an extensive background in corporate financing having served as President of Triangle Bank (North Carolina) and Senior Vice President of BB&T (North Carolina). Prior to joining Calvert Holdings, Inc. in 2003, he was Managing Director of two asset-based lending funds. In addition to his responsibilities with Calvert Corporate Funding, Andy is President of Carolina Securities, Inc. and corporate Vice President of Calvert Research, LLC, a business unit focused on development of new drug therapeutics.
Mr. Burch graduated from East Carolina University, The Young Executive Program at University of North Carolina (Chapel Hill), and The School of Banking of the South at Louisiana State University. He also holds basic and standard certificates from the American Institute of Banking, FINRA Series 7, 63, and 23 securities licenses and a NC Real Estate Broker License.
Lonnie Bookbinder, PhD
West Coast Regional Director
Dr. Lonnie Bookbinder has worked in the biopharmaceutical industry since 1969 holding multiple positions in pharmaceutical and laboratory sales as well as clinical research before founding his first company, in 1982, providing management and marketing services to doctors, hospitals and companies in the diagnostic and pharmaceutical industry. In 1990, he joined Russ McLauchlan as Director of Business Development at Immunomedics and then held senior VP positions at Nycomed-Salutar, Ribi ImmunoChem and later became COO of CellPath. In 1998, Dr. Bookbinder provided CEO and Board-level guidance to young biotech companies and subsequently co-founded several companies with long-time business associates.
In 2007, Lonnie re-joined Russ McLauchlan as West Coast Regional Director of Calvert Research, to represent the company as a potential strategic partner for universities, researchers and biotech companies seeking to develop innovative drug candidates.
Sara Shen
Business Analyst
Sara Shen is originally from Shanghai, China and holds an MBA and MS degree in Economics from the University of Central Florida. She also has a degree in Applied Mathematics from Tongji University in Shanghai. Sara’s focus at Calvert Research includes research and analysis of potential investments and markets.
Anthony Yousefnejad
Business Analyst
Prior to joining Calvert Research in 2011, Anthony enjoyed a successful seven year sales career with AstraZeneca, one of the top-tier, research-based, biopharmaceutical companies in the world. During his tenure, Anthony worked closely with an experienced pharmaceutical sales and marketing team to develop and execute brand strategy and cultivated close working relationships with key medical thought leaders across many different therapeutic areas. His experience spans over several blockbuster drugs in the marketplace that have achieved multi-billion dollar annual revenues, including Nexium, Crestor, Seroquel, Symbicort, Atacand, and Toprol-XL.
Anthony attended the Poole College of Management at North Carolina State University where he earned his bachelor’s degree. Anthony also holds an MBA from the Jenkins Graduate School of Management at North Carolina State University.
